Phase 1B, Pilot Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety, Activity of Pembrolizumab Administered Intra-lymphatically Using the Sofusa DoseConnect in Patients With Relapsed/Refractory Cutaneous T- Cell Lymphoma (CTCL)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Cutaneous T-cell lymphoma; Mycosis fungoides
Focus Pharmacodynamics
Sponsors Sorrento Therapeutics

Most Recent Events

08 Jul 2022 Planned End Date changed from 31 Aug 2022 to 27 Mar 2024.
08 Jul 2022 Planned primary completion date changed from 31 Jul 2022 to 29 Jan 2024.
08 Jul 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight